28 investors have funded 12 Life Sciences companies head-officed in Heidelberg, across 47 rounds (Mar 2001 – Jul 2024). They are ranked by how many Heidelberg companies in this market they have actually backed.
"In Heidelberg" describes the companies, not the investor: most of the money in any city comes from somewhere else, and the Where the money comes from section below shows exactly where it came from here.
Ranked by companies backed in this market and city, then by round count. "Led" counts rounds recorded with this investor as lead.
| # | Investor | Based in | Stages here | Companies | Rounds | Led | Latest | Portfolio total |
|---|---|---|---|---|---|---|---|---|
| 1 | HTGF | Bonn, Germany | Seed | 4 | 4 | 3 | Jul 2024 | 672 |
| 2 | Dievini | Walldorf, Germany | Series CSeries BPE | 3 | 4 | 4 | Dec 2021 | 7 |
| 3 | Life Sciences Partners | Amsterdam, Netherlands | Series ASeries DSeries B | 2 | 3 | — | Jan 2017 | 105 |
| 4 | BioMedPartners | Basel, Switzerland | Series CSeries DSeries B | 1 | 3 | — | Oct 2012 | 49 |
| 5 | Novo Nordisk | Bagsvaerd, Denmark | Series CSeries DSeries B | 1 | 3 | — | Oct 2012 | 14 |
| 6 | Index Ventures | London, United Kingdom | Series BSeries C | 1 | 2 | — | Mar 2003 | 639 |
| 7 | Orbimed | New York City, United States | Series DSeries B | 1 | 2 | — | Oct 2012 | 422 |
| 8 | Atlas Venture | Cambridge, United States | Series BSeries C | 1 | 2 | — | Mar 2003 | 302 |
| 9 | Advent Life Sciences | London, United Kingdom | Series BSeries C | 1 | 2 | — | Mar 2003 | 66 |
| 10 | Sofinnova Partners | Paris, France | Series BSeries C | 1 | 2 | — | Mar 2003 | 45 |
| 11 | Schroders | London, United Kingdom | Series BSeries C | 1 | 2 | — | Mar 2003 | 50 |
| 12 | Calibrium | Zurich, Switzerland | Series CSeries D | 1 | 2 | — | Oct 2012 | 19 |
| 13 | EQT | Stockholm, Sweden | Seed | 1 | 1 | — | Jan 2015 | 205 |
| 14 | KfW | Frankfurt Am Main, Germany | Series B | 1 | 1 | — | Oct 2005 | 128 |
| 15 | Invesco | Atlanta, United States (Usa) | Series C | 1 | 1 | — | Mar 2003 | 90 |
| 16 | Societe Generale | Paris, France | Series C | 1 | 1 | — | Mar 2003 | 88 |
| 17 | LBBW Venture Capital | Stuttgart, Germany | Seed | 1 | 1 | — | Jul 2024 | 35 |
| 18 | SHS | Tubingen, Germany | Series B | 1 | 1 | — | Oct 2005 | 32 |
| 19 | EMBL Ventures | Heidelberg, Germany | Series A | 1 | 1 | — | Jan 2017 | 17 |
| 20 | CARMA FUND | Munich, Germany | Seed | 1 | 1 | — | Jul 2024 | 11 |
| 21 | Biofrontier Partners | Chuo City, Japan | Series C | 1 | 1 | — | Mar 2003 | 6 |
| 22 | SLS Venture | Stockholm, Sweden | Series A | 1 | 1 | 1 | May 2012 | 6 |
| 23 | GreyBird Ventures | Concord, United States | Seed | 1 | 1 | — | Jan 2016 | 7 |
| 24 | Epignostix | Heidelberg, Germany | Seed | 1 | 1 | — | Jul 2024 | 1 |
| 25 | EMBL | Barcelona, Spain | Series A | 1 | 1 | — | Jan 2017 | 1 |
| 26 | Heidelberg University | Heidelberg, Germany | Seed | 1 | 1 | — | Jul 2024 | 1 |
| 27 | German Cancer Research Center | Germany | Seed | 1 | 1 | — | Jul 2024 | 1 |
| 28 | Heidelberg University Hospital | Heidelberg, Germany | Seed | 1 | 1 | — | Jul 2024 | 1 |
Head office of the investors on this page.
Rounds by stage — where in a company's life this money arrives.
Total disclosed size of each round, not one investor's share.
How active this market has been.
Life Sciences companies head-officed in Heidelberg that took money from these investors.
| Company | Backers | Rounds | Disclosed | Latest round |
|---|---|---|---|---|
| Cellzome cellzome.com |
8 | 13 | $532M | Series C Mar 2003 |
| Affimed Therapeutics affimed.com |
7 | 14 | $290.8M | Series D Oct 2012 |
| Epignostix epignostix.com |
7 | 7 | $32.3M | Seed Jul 2024 |
| Luxendo luxendo.eu |
4 | 4 | $25.3M | Series A Jan 2017 |
| Apogenix apogenix.com |
1 | 2 | $72.3M | Series B Dec 2021 |
| Novaliq novaliq.com |
1 | 1 | $53M | Series C Oct 2018 |
| Molecular Health molecularhealth.com |
1 | 1 | $26.9M | PE Nov 2015 |
| BioPheresis biopheresis.de |
1 | 1 | $8.3M | Series A May 2012 |
| PEPperPRINT pepperprint.com |
1 | 1 | $676K | Seed Mar 2010 |
| Perora perora.com |
1 | 1 | — | Seed Sep 2013 |
| Tolerogenixx tolerogenixx.com |
1 | 1 | — | Seed May 2017 |
| Hummingbird Diagnostics hummingbird-diagnostics.com |
1 | 1 | — | Seed Jan 2016 |
| Date | Investor | Company | Stage | Round size |
|---|---|---|---|---|
| Jul 2024 | Heidelberg University Hospital | Epignostix | Seed | $4.6M |
| Jul 2024 | Heidelberg University | Epignostix | Seed | $4.6M |
| Jul 2024 | German Cancer Research Center | Epignostix | Seed | $4.6M |
| Jul 2024 | HTGF | Epignostix | Seed | $4.6M |
| Jul 2024 | LBBW Venture Capital | Epignostix | Seed | $4.6M |
| Jul 2024 | CARMA FUND | Epignostix | Seed | $4.6M |
| Jul 2024 | Epignostix | Epignostix | Seed | $4.6M |
| Dec 2021 | DieviniLED | Apogenix | Series B | $29.4M |
| Oct 2018 | DieviniLED | Novaliq | Series C | $53M |
| May 2017 | HTGFLED | Tolerogenixx | Seed | — |
| Jan 2017 | EMBL Ventures | Luxendo | Series A | $8.4M |
| Jan 2017 | EMBL | Luxendo | Series A | $8.4M |
| Jan 2017 | Life Sciences Partners | Luxendo | Series A | $8.4M |
| Jan 2016 | GreyBird Ventures | Hummingbird Diagnostics | Seed | — |
| Nov 2015 | DieviniLED | Molecular Health | PE | $26.9M |
| Jan 2015 | EQT | Luxendo | Seed | — |
| Sep 2013 | HTGFLED | Perora | Seed | — |
| Oct 2012 | Life Sciences Partners | Affimed Therapeutics | Series D | $20.1M |
| Oct 2012 | BioMedPartners | Affimed Therapeutics | Series D | $20.1M |
| Oct 2012 | Orbimed | Affimed Therapeutics | Series D | $20.1M |
Life Sciences investors in other cities